Akt3 Antibody [3B12F3F10 / 2D2B11B11 / 2D2B11H5] | 32-106

Akt3 Antibody [3B12F3F10 / 2D2B11B11 / 2D2B11H5] | 32-106 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Ni-NTA purified truncated recombinant Akt3 expressed in E. Coli strain BL21 (DE3) .

Research Area: Signal Transduction

Tested Application: E, WB

Application: Western Blot:1:500 - 1:2000
ELISA:Propose dilution 1:10, 000.
Determining optimal working dilutions by titration test.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: 3B12F3F10 / 2D2B11B11 / 2D2B11H5

Isotype: N/A

Conjugate: Unconjugated

Physical State: N/A

Buffer: Ascitic fluid containing 0.03% sodium azide.

Concentration: N/A

Storage Condition: Akt3 monoclonal antibody can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: PKBG, Protein kinase Akt-3, PKB gamma, MPPH, PKBG, PRKBG, STK-2, PKB-GAMMA, RAC-gamma, RAC-PK-gamma

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Akt3 (also designated protein kinase B gamma or v-akt murine thymoma viral oncogene homolog 3) ，with 479-amino acid protein (about 53 kDa) , belongs to the AKT serine/threonine protein kinase family, which also includes Akt1 and Akt2. AKT kinases are known to be regulators of cell signaling in response to insulin and growth factors. They are involved in a wide variety of biological processes including cell proliferation, differentiation, apoptosis, tumorigenesis, as well as glycogen synthesis and glucose uptake.Akt3 is not required for the maintenance of normal carbohydrate metabolism but is essential for the attainment of normal organ size. Identifying Akt3 as a selective target in melanoma cells also provides new therapeutic opportunities for patients in the advanced stages of this disease.